miRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling

Cell Cycle

Volumn 11, Issue 7, 2012, Pages 1273-1281

  Cha, Yong Hoon ^a   Kim, Nam Hee ^a   Park, Changbum ^a   Lee, Inhan ^b   Kim, Hyun Sil ^a   Yook, Jong In ^a  

^a Yonsei University College of Dentistry   (South Korea)

^b MiRcore   (United States)

Author keywords

Cancer; Epithelial mesenchymal transition; MicroRNA 34; p53; Wnt signaling

Indexed keywords

DNA; MICRORNA; MICRORNA 34; PROTEIN P53; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER INVASION; CANCER STEM CELL; CELL AGING; CELL CYCLE ARREST; DNA BINDING; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; HUMAN; NONHUMAN; UNTRANSLATED REGION;

GASTROPODA;

EID: 84860319933     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19618     Document Type: Article

References (86)

1. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12; PMID:18431400; http://dx.doi.org/10.1038/nrm2395.
2. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21; PMID:1552940; http://dx.doi.org/ 10.1038/356215a0.
3. Donehower LA, Lozano G. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 2009; 9:831-41; PMID:19776746; http://dx.doi.org/10.1038/nrc2731.
4. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82:675-84; PMID:7664346; http://dx.doi.org/10.1016/0092- 8674(95)90039-X.
5. Jones JM, Attardi L, Godley LA, Laucirica R, Medina D, Jacks T, et al. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 1997; 8:829-38; PMID:9269892.
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10; PMID:11099028; http://dx.doi.org/10.1038/35042675.
7. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989; 86:8763-7; PMID:2530586; http://dx.doi. org/10.1073/pnas.86.22.8763.
8. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57:1083-93; PMID:2525423; http://dx.doi.org/10.1016/0092-8674(89)90045-7.
9. Cagatay T, Ozturk M. p53 mutation as a source of aberrant beta-catenin accumulation in cancer cells. Oncogene 2002; 21:7971-80; PMID:12439747; http://dx.doi.org/10.1038/sj.onc.1205919.
10. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Downregulation of beta-catenin by activated p53. Mol Cell Biol 2001; 21:6768-81; PMID:11564862; ht tp: //dx.doi .org/10.1128/MCB.21.20.6768-81.2001.
11. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, et al. Impact of p53 loss on reversal and recurrence of conditional Wntinduced tumorigenesis. Genes Dev 2003; 17:488- 501; PMID:12600942; http://dx.doi.org/10. 1101/gad.1051603.
12. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8:387-98; PMID:18432252; http://dx.doi. org/10.1038/nrc2389.
13. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653:1-24; PMID:12781368.
14. Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, Espada J, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006; 25:4116- 21; PMID:16491118; http://dx.doi.org/10.1038/sj.onc.1209439.
15. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004; 84:465-78; PMID:14968126; http://dx.doi.org/10.1038/labinvest.3700068.
16. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36:417-22; PMID:15034581; http://dx.doi.org/10.1038/ng1330.
17. Yook JI, Li XY, Ota I, Fearon ER, Weiss SJ. Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem 2005; 280:11740-8; PMID:15647282; http://dx.doi.org/10.1074/jbc.M413878200.
18. Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 2006; 8:1398-406; PMID:17072303; http://dx.doi.org/10.1038/ncb1508.
19. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83; PMID:10655586; http://dx.doi.org/10.1038/35000025.
20. Rowe RG, Li XY, Hu Y, Saunders TL, Virtanen I, Garcia de Herreros A, et al. Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. J Cell Biol 2009; 184:399- 408; PMID:19188491; http://dx.doi.org/10.1083/jcb.200810113.
21. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045- 5.
22. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75:855-62; PMID:8252622; http://dx.doi.org/10.1016/0092- 8674(93)90530-4.
23. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37:495-500; PMID:15806104; http://dx.doi.org/10.1038/ng1536.
24. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20; PMID:15652477; http://dx.doi.org/10.1016/j.cell.2004.12.035.
25. Mavrakis KJ, Wendel HG. TargetScreen: an unbiased approach to identify functionally important microRNA targets. Cell Cycle 2010; 9:2080- 4; PMID:20505335; http://dx.doi.org/10.4161/cc.9.11.11807.
26. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, et al. New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res 2009; 19:1175-83; PMID:19336450; http://dx.doi.org/10.1101/gr.089367.108.
27. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4:199-227; PMID:18817506; http://dx.doi.org/10.1146/annurev.pathol.4.110807.092222.
28. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/nature03702.
29. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F and Myc. Proc Natl Acad Sci USA 2008; 105:19678-83; PMID:19066217; http://dx.doi.org/10.1073/pnas.0811166106.
30. He L, Thomson JM, Hemann MT, Hernando- Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435:828-33; PMID:15944707; http://dx.doi.org/10.1038/nature03552.
31. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39:673-7; PMID:17401365; http://dx.doi.org/10.1038/ng2003.
32. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52; PMID:17540599; http://dx.doi.org/10.1016/j.molcel.2007.05.010.
33. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447:1130- 4; PMID:17554337; http://dx.doi.org/10.1038/nature05939.
34. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4:6816; PMID:19714243; http://dx.doi.org/10.1371/journal.pone.0006816.
35. Merkel O, Asslaber D, Piñón JD, Egle A, Greil R. Interdependent regulation of p53 and miR- 34a in chronic lymphocytic leukemia. Cell Cycle 2010; 9:2764-8; PMID:20581456; http://dx.doi. org/10.4161/cc.9.14. 12267.
36. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26:731-43; PMID:17540598; http://dx.doi.org/10.1016/j. molcel.2007.05.017.
37. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6:1586-93; PMID:17554199; http://dx.doi.org/10.4161/cc.6.13.4436.
38. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 2011; 4:71; PMID:22045851; http://dx.doi.org/10.1126/scisignal.2001744.
39. Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, et al. A p53/miRNA-34 axis regulates Snail1- dependent cancer cell epithelial-mesenchymal transition. J Cell Biol 2011; 195:417-33; PMID:22024162; http://dx.doi.org/10.1083/jcb. 201103097.
40. Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, Lee B. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood 2009; 114:404-14; PMID:19398721; http://dx.doi.org/10.1182/blood-2008-09-179150.
41. Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10:4256-71; PMID:22134354; http://dx.doi.org/10.4161/cc.10.24.18552.
42. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17:1298-307; PMID:17656095; http:// dx.doi.org/10.1016/j.cub.2007.06.068.
43. Marcet B, Chevalier B, Luxardi G, Coraux C, Zaragosi LE, Cibois M, et al. Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol 2011; 13:693-9; PMID:21602795.
44. Lizé M, Klimke A, Dobbelstein M. MicroRNA-449 in cell fate determination. Cell Cycle 2011; 10:2874-82; PMID:21857159; http://dx.doi.org/10. 4161/cc.10.17.17181.
45. Noonan EJ, Place RF, Basak S, Pookot D, Li LC. miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 2010; 1:349-58; PMID:20948989.
46. Cannell IG, Bushell M. Regulation of Myc by miR-34c: A mechanism to prevent genomic instability? Cell Cycle 2010; 9:2726-30; PMID:20603603; http://dx.doi.org/10.4161/cc.9.14.12182.
47. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, et al.; Children's Oncology Group. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353:2243-53; PMID:16306521; http://dx.doi.org/10.1056/ NEJMoa052399.
48. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res 2008; 68:2551-6; PMID:18413720; http://dx.doi.org/10.1158/0008-5472.CAN-07-2095.
49. Bale SJ, Dracopoli NC, Tucker MA, Clark WH Jr, Fraser MC, Stanger BZ, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320:1367-72; PMID:2716782; http://dx.doi.org/10.1056/NEJM198905253202102.
50. Schwab M, Praml C, Amler LC. Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 1996; 16:211-29; PMID:8875235; http://dx.doi.org/10.1002/(S ICI)1098-2264(199608)16:4<211::AID-GCC1>3.0. CO;2-0.
51. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101:2999-3004; PMID:14973191; http://dx.doi.org/10.1073/pnas.0307323101.
52. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26:5017-22; PMID:17297439; http://dx.doi.org/10.1038/sj.onc.1210293.
53. Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and Tp53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol 2009; 68:1219-28; PMID:19816195; http://dx.doi.org/10.1097/ NEN.0b013e3181bee1f1.
54. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002; 103:267-75; PMID:11907807; http://dx.doi. org/10.1007/s004010100464.
55. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244:217-21; PMID:2649981; http://dx.doi.org/10.1126/science. 2649981.
56. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9; PMID:11309270.
57. Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-smallcell lung cancer. Carcinogenesis 2009; 30:1903-9; PMID:19736307; http://dx.doi.org/10.1093/carcin/bgp219.
58. Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008; 214:17-24; PMID:17948228; http://dx.doi.org/10.1002/path.2251.
59. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7:2591-600; PMID:18719384; http://dx.doi.org/10. 4161/cc.7.16.6533.
60. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67:1424-9; PMID:17308079; http://dx.doi.org/10.1158/ 0008-5472.CAN-06-4218.
61. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008; 68:4123-32; PMID:18519671; http://dx.doi.org/10.1158/0008-5472.CAN-08-0325.
62. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC Tp53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19:607-14; PMID:12007217; http://dx.doi.org/10.1002/humu.10081.
63. Miska EA, Alvarez-Saavedra E, Abbott AL, Lau NC, Hellman AB, McGonagle SM, et al. Most Caenorhabditis elegans microRNAs are individually not essential for development or viability. PLoS Genet 2007; 3:215; PMID:18085825; http://dx.doi. org/10.1371/journal.pgen.0030215.
64. Park CY, Choi YS, McManus MT. Analysis of microRNA knockouts in mice. Hum Mol Genet 2010; 19:169-75; PMID:20805106; http://dx.doi. org/10.1093/hmg/ ddq367.
65. Rane S, Sayed D, Abdellatif M. MicroRNA with a MacroFunction. Cell Cycle 2007; 6:1850-5; PMID:17660716; http://dx.doi.org/10.4161/cc.6.15.4551.
66. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433:769-73; PMID:15685193; http://dx.doi.org/10.1038/ nature03315.
67. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4:721-6; PMID:17694064; http://dx.doi.org/10.1038/nmeth1079.
68. Cazalla D, Yario T, Steitz JA. Downregulation of a host microRNA by a Herpesvirus saimiri noncoding RNA. Science 2010; 328:1563-6; PMID:20558719; http://dx.doi.org/10.1126/science.1187197.
69. Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB. Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res 2011; 39:3026-41; PMID:21149267; http://dx.doi.org/10.1093/nar/gkq1003.
70. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465:1033-8; PMID:20577206; http://dx.doi.org/10.1038/ nature09144.
71. Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011; 147:370-81; PMID:22000015; http://dx.doi.org/10.1016/j.cell.2011.09.041.
72. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011; 147:344-57; PMID:22000013; http://dx.doi.org/10. 1016/j.cell.2011.09.029.
73. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010; 42:454-8; PMID:20400965; http://dx.doi. org/10.1038/ng.556.
74. Pérez-Mancera PA, Pérez-Caro M, González-Herrero I, Flores T, Orfao A, de Herreros AG, et al. Cancer development induced by graded expression of Snail in mice. Hum Mol Genet 2005; 14:3449-61; PMID:16207734; http://dx.doi.org/10.1093/hmg/ddi373.
75. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011; 476:163-9; PMID:21833082; http://dx.doi. org/10.1038/nature10275.
76. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013.
77. Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family crosstalk meets therapeutic opportunity. Oncotarget 2011; 2:259-64; PMID:21436470.
78. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67; PMID:2188735; http://dx.doi.org/10.1016/0092-8674(90) 90186-I.
79. Hafner C, Toll A, Fernández-Casado A, Earl J, Marqués M, Acquadro F, et al. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci USA 2010; 107:20780-5; PMID:21078999; http:// dx.doi.org/10.1073/pnas.1008365107.
80. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41:544-52; PMID:19282848; http://dx.doi.org/10.1038/ng.356.
81. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005; 15:249-54; PMID:15694309; http://dx.doi. org/10.1016/j.cub.2005.01.031.
82. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-59; PMID:19682730; http://dx.doi.org/10.1016/j. cell.2009.06.034.
83. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009; 138:1083-95; PMID:19766563; http://dx.doi.org/10. 1016/j.cell.2009.06.048.
84. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007; 104:618-23; PMID:17202265; http://dx.doi.org/10.1073/pnas.0606599104.
85. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi. org/10.1016/j.cell.2008. 03.027.
86. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27:2059-68; PMID:19544473; http://dx.doi.org/10.1002/stem.154.